What do systematic reviews say?

Tacrolimus vs cyclosporin

Tacrolimus may leads to higher diabetes mellitus compared with cyclosporin (low certainty).

• Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients 2013 · Cochrane Headline outcomes only
  RR 4.24 [1.58, 11.4]
  2 studies · 164 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 1.9 [0.66, 5.46]
  2 studies · 82 participants
  Low

Mycophenolate mofetil vs cyclosporin

The review found no eligible studies for this question.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mycophenolate mofetil vs cyclosporin

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 3 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.3 [0.09, 1.07]
  3 studies · 144 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.23 [0.1, 0.5]
  3 studies · 140 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.64 [0.08, 4.85]
  2 studies · 84 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.09 [0.02, 0.47]
  3 studies · 144 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: reduced GFR compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.45]
  1 study · 24 participants
  Low

Alkylating agents vs cyclosporin

Alkylating agents showed no clear difference in relapse at end of therapy (6 to 9 months) compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.91 [0.55, 1.48]
  2 studies · 95 participants
  Low

Alkylating agents vs cyclosporin

Alkylating agents may leads to lower relapse at 12 to 24 months compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.51 [0.35, 0.74]
  2 studies · 95 participants
  Low

Alkylating agents vs cyclosporin

The review found no eligible studies for this question.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alkylating agents vs cyclosporin

The review found no eligible studies for this question.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alkylating agents vs cyclosporin

Alkylating agents showed no clear difference in adverse effects: serum creatinine compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.2 [0.02, 1.69]
  2 studies · 106 participants
  Low

Alkylating agents vs cyclosporin

Alkylating agents may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.06 [0.01, 0.4]
  2 studies · 106 participants
  Low

Alkylating agents vs cyclosporin

Alkylating agents may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.08 [0.01, 0.59]
  2 studies · 106 participants
  Low

Alkylating agents vs cyclosporin

It is very uncertain whether alkylating agents changes adverse effects: hypertension compared with cyclosporin (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.72]
  1 study · 40 participants
  Very low

Alkylating agents vs cyclosporin

It is very uncertain whether alkylating agents changes adverse effects: leucopenia compared with cyclosporin (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 29.84 [1.84, 483.93]
  1 study · 66 participants
  Very low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 6 months: complete remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.14 [0.64, 2.03]
  1 study · 41 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 6 months: complete and partial remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.57 [0.16, 2.08]
  1 study · 41 participants
  Low
• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.05 [0.87, 1.25]
  2 studies · 58 participants
  Low